Kenya has received 21,000 starter doses of Lenacapavir for HIV prevention. The long-acting injectable drug supports pre-exposure prophylaxis, commonly known as PrEP. This delivery marks the first phase of Kenya’s national rollout. Additionally, it reinforces the country’s commitment to